newsfilter
← Latest News
Business Wire·

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

  • Vistagen (NASDAQ: VTGN) will host a conference call & webcast on Thursday, February 12, 2026, at 2:00 p.m. Pacific Time to report Q3 2026 fiscal results ended December 31, 2025, & provide a corporate update.
  • The live webcast link is available under "Events" in the Investors section of the company website & will be archived for at least 90 days.
  • Participants may pre-register via dial-in using the provided link to receive access details via email.
  • Vistagen is a late clinical-stage biopharmaceutical company developing pherines, a class of intranasal products leveraging nose-to-brain neurocircuitry.
  • Pherine candidates aim to deliver therapeutic benefits without blood absorption or brain uptake, potentially offering a safer alternative to other pharmacological options.
  • The pherine pipeline includes five investigational candidates targeting social anxiety disorder, major depressive disorder, & vasomotor symptoms due to menopause.
  • Investor inquiries can be directed to Mark A. McPartland at markmcp@vistagen.com.
  • Media inquiries can be directed to Michelle P. Wellington at mwellington@vistagen.com.